pentobarbital will reduce the level or effect of pioglitazone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unknown.
pentobarbital will decrease the level or result of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unfamiliar.
pentobarbital will reduce the extent or result of tofacitinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Loss of, or lessened response to tofacitinib may perhaps manifest when coadministered with strong CYP3A4 inducers
pentobarbital will lower the extent or effect of ramelteon by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
pentobarbital will lessen the extent or impact of fesoterodine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lower the extent or effect of carbamazepine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Observe Intently (1)pentobarbital will minimize the level or result of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Use of alternative treatments is strongly recommended when linagliptin will be to be administered using a CYP3A4 inducer
pentobarbital will reduce the extent or outcome of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will reduce the level or result of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Mysterious.
pentobarbital will decrease the extent or influence of tacrolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will lower the extent or influence of sulfamethoxazole by impacting hepatic enzyme CYP2C9/10 metabolism. Slight/Significance Unfamiliar.
Keep track of Intently (1)pentobarbital will lessen the extent or outcome of fentanyl intranasal by impacting hepatic/intestinal website enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers may lead into a reduce in fentanyl plasma concentrations, lack of efficacy or, possibly, improvement of the withdrawal syndrome in the affected individual that has created Actual physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the results from the inducer decrease, the fentanyl plasma focus will boost which could maximize or prolong the two the therapeutic and adverse consequences.
Check Carefully (1)pentobarbital will minimize the extent or outcome of tadalafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the level or outcome of roflumilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not suggested; strong cytochrome P450 enzyme inducers reduce systemic publicity to roflumilast and may decrease the therapeutic efficiency